Corgentech Announces Appointment of Susan Kramer as Vice President of Preclinical Development
30 Mai 2006 - 2:30PM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., May 30 /PRNewswire-FirstCall/ --
Corgentech Inc. (NASDAQ:CGTK) today announced the appointment of
Susan Kramer, Dr.P.H. as vice president of preclinical development.
"Susan's more than 20 years of leading research, preclinical and
clinical development programs will be instrumental in providing
robust support for our future clinical programs and advancement of
pain products into our development pipeline," said John P.
McLaughlin, chief executive officer of Corgentech. Dr. Kramer joins
Corgentech from BAS Medical, where she was a co-founder and served
as vice president of research and development from 2003 to 2006.
She was instrumental in the initiation of the company's preclinical
and clinical programs. Prior to BAS Medical, Dr. Kramer worked at
Genentech for 18 years in a number of roles of increasing
management responsibility, including director of product
development, senior director of bioanalytical technology and
ultimately as senior director of development sciences operations
and strategic planning. She served as project team leader for
products Actimmune(R) and Raptiva(R). She led numerous pharmacology
teams and served on several key committees, including the Product
Development Committee. Prior to Genentech, Dr. Kramer served as the
director of Medical Laboratories in Montes Claros, Minas Gerais,
Brazil as a Peace Corps Volunteer, followed by a stint as head of
the clinical virology laboratory at the UCSF Medical Center at the
onset of the AIDS epidemic. Dr. Kramer holds Dr.P.H. and M.P.H.
degrees in Biomedical Sciences from the University of California,
Berkeley. About Corgentech Corgentech is a late-stage
biopharmaceutical company that seeks to be the leader in the
development and commercialization of novel therapeutic treatments
for pain. The company has four drug candidates in clinical
development for multiple potential indications, the most advanced
of which, 3268, has completed Phase 3 clinical trials. To reflect
the company's core focus on novel pain management therapies, the
board of directors recently voted to change the company name to
Anesiva. If approved by stockholders at the annual meeting on June
21, 2006, the name change will become effective immediately
thereafter. Corgentech is based in South San Francisco, CA. Forward
Looking Statements This press release includes "forward-looking
statements" within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995.
Words such as "expect," "estimate," "project," "budget,"
"forecast," "anticipate," "intend," "plan," "may," "will," "could,"
"should," "believes," "predicts," "potential," "continue," and
similar expressions are intended to identify such forward-looking
statements. Forward-looking statements in this press release
include, without limitation, projected timing of clinical
development and other matters that involve known and unknown risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance or achievements to differ
materially from results expressed or implied by this press release.
Such risk factors include, among others: whether Corgentech can
successfully develop new products and the degree to which these
gain market acceptance. Actual results may differ materially from
those contained in the forward-looking statements in this press
release. Additional information concerning these and other risk
factors is contained in Corgentech's quarterly report on Form 10-Q
for the quarter ended March 31, 2006. Corgentech undertakes no
obligation and does not intend to update these forward-looking
statements to reflect events or circumstances occurring after this
press release. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement. DATASOURCE:
Corgentech Inc. CONTACT: Richard Powers, Chief Financial Officer of
Corgentech Inc., +1-650-624-9600, or ; or Media, Daryl Messinger,
WeissComm Partners, +1-415-999-2361, or , for Corgentech Inc. Web
site: http://www.corgentech.com/
Copyright
Corgentech (NASDAQ:CGTK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Corgentech (NASDAQ:CGTK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024